Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.
This article was originally published in The Gray Sheet
Executive Summary
An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.
You may also be interested in...
MiniMed Faces FDA Panel For Consumer Glucose Sensor; Dampens Outlook
MiniMed's home-use continuous glucose monitoring system (CGMS) could be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Panel as early as May 9, the company says.
MiniMed Faces FDA Panel For Consumer Glucose Sensor; Dampens Outlook
MiniMed's home-use continuous glucose monitoring system (CGMS) could be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Panel as early as May 9, the company says.
Cardiac Science May Pursue Hostile Bid For Spacelabs Installed Monitor Base
Spacelabs Medical's deferring of a decision on Cardiac Science, Inc.' s (CSI) second merger offer in two weeks could lead to a hostile takeover bid to acquire Spacelabs' installed base of about 65,000 hospital patient monitors.